$SNEX

Rotsztain Diego sold $1.5M of SNEX

Rotsztain Diego (Chief Governance/Legal Officer) sold 20,630 shares of StoneX Group Inc. (SNEX) at $74.40 ($1.53M total) on 2026-07-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rotsztain Diego
Published Jul 27, 2026, 11:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 27, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
high confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

The disclosed sale provides transparency on insider activity but does not, by itself, change expected cash flows, guidance, or regulatory/operational risk.

02

Market read

Traders may log the transaction for sentiment monitoring, but it is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not indicate why the sale occurred (tax, diversification, planned liquidity), so the signal-to-noise is low without additional context like concurrent buys or changes in guidance.

Relevance 5/10Novelty 3/10Timing: Filed July 27, covering a sale executed July 24.

Background

The article is a Form 4 insider transaction disclosure for StoneX Group Inc., reported by an officer under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$SNEXNeutralHigh confidence
Context

StoneX Group insider Diego Rotsztain sold 20,630 shares at $74.4007 on a 10b5-1 plan, totaling about $1.53M.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 discloses the transaction size and that it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single officer 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with private views on near-term risk, so traders may still watch for follow-on disclosures.

Key entities

  • StoneX Group Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Diego Rotsztain

    Chief Governance/Legal Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive weight of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.